Check for updates

OPEN ACCESS

EDITED BY Tzvi Dwolatzky, Technion – Israel Institute of Technology, Israel

REVIEWED BY

Horia Haragus, Victor Babeş University of Medicine and Pharmacy, Romania Sanjay Rai, Base Hospital Delhi Cantt, India

*CORRESPONDENCE Jiangang Wang ⊠ 116774347@qq.com Wei Jiang ⊠ 390373532@qq.com

SPECIALTY SECTION This article was submitted to Geriatric Medicine, a section of the journal Frontiers in Medicine

RECEIVED 31 October 2022 ACCEPTED 16 January 2023 PUBLISHED 02 February 2023

CITATION

Fu M, Shen J, Ren Z, Lv Y, Wang J and Jiang W (2023) A systematic review and meta-analysis of cemented and uncemented bipolar hemiarthroplasty for the treatment of femoral neck fractures in elderly patients over 60 years old.

Front. Med. 10:1085485. doi: 10.3389/fmed.2023.1085485

COPYRIGHT

© 2023 Fu, Shen, Ren, Lv, Wang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A systematic review and meta-analysis of cemented and uncemented bipolar hemiarthroplasty for the treatment of femoral neck fractures in elderly patients over 60 years old

Mengyu Fu¹, Jieliang Shen², Zhoukui Ren¹, Yingwen Lv¹, Jiangang Wang^{1*} and Wei Jiang^{2*}

¹Department of Orthopaedics, The Thirteenth People's Hospital of Chongqing (The Geriatric Hospital of Chongqing), Chongqing, China, ²Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Background: Currently, whether bone cement can be applied in bipolar hemiarthroplasty to treat femoral neck fractures (FNFs) in elderly patients is controversial. The aim of this systematic review and meta-analysis was to compare the effectiveness and safety of cemented bipolar hemiarthroplasty (CBH) versus uncemented bipolar hemiarthroplasty (UCBH) in the treatment of FNFs among elderly patients over 60 years old.

Materials and methods: The Pubmed, Web of science, Cochrane Library and EMBASE databases were searched comprehensively for relevant articles from their inception to May 2022. Studies about comparing outcomes between CBH and UCBH for FNFs in elderly patients aged more than 60 years were included. Outcomes including operation time, intra-operative blood loss, length of hospital stay, wound infections, residual pain, revisions, re-operations, complications related to prosthesis, general complications, and mortality. The Review Manager 5.3 software provided by the Cochrane Collaboration Network was used to perform the meta-analysis of comparable data.

Results: A total of 6 randomized controlled trials (RCTs) and 9 observational studies were included in this analysis, with 33,118 patients (33,127 hips). Results of the metaanalysis indicated that the operation time [WMD = 13.01 min, 95% CI (10.79, 15.23)], intra-operative blood loss [WMD = 80.57 ml, 95% CI (61.14, 99.99)], incidence of heterotrophic ossification [OR = 2.07, 95% CI (1,14, 3.78)], were increased in the CBH group but the incidence of intra-operative fractures [OR = 0.24, 95% CI (0.07, 0.86)], periprosthetic fractures [OR = 0.24, 95% CI (0.18, 0.31)], aseptic loosening of prosthesis [OR = 0.20, 95% CI (0.09, 0.44)], wound infections [OR = 0.80, 95% CI (0.68, 0.95)] and re-operation rates [OR = 0.61, 95% CI (0.54, 0.68)] were lower in the CBH group by comparison with the UCHB group. However, there were no significant differences in residual pain, length of hospital stay, prosthetic dislocation, prosthetic subsidence (> 5 mm), acetabulum erosion, revisions, pulmonary infections, pulmonary embolisms, urinary tract infections, deep venous thromboses, decubitus, cardiovascular accidents (arrhythmia/myocardial infarction), and respiratory failure between the two groups. In terms of mortality, perioperative mortality (within 72 h) [OR = 2.39, 95% CI (1.71, 3.32)] and 1-week mortality postoperatively [OR = 1.22, 95% CI (1.05, 1.41)] in CBH group were higher than those in UCBH group, but there were no significant differences in mortality at 1 month, 3 months, 1 year, and 2 years postoperatively between CBH group and UCBH group.

Conclusion: This meta-analysis found that elderly patients over 60 years old with FNFs who underwent CBH had longer operation time, higher incidence of heterotrophic ossification, intra-operative blood loss, and mortality within 72 h of operation and at 1-week postoperatively, but lower incidence of periprosthetic fractures, aseptic loosening of prosthesis, intra-operative fractures, wound infections and re-operations. Other outcomes were not significantly different between the two groups.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021274253

KEYWORDS

femoral neck fractures, elderly patients, cemented, uncemented, bipolar hemiarthroplasty, meta-analysis

1. Introduction

Due to an aging population, the annual incidence of osteoporosis is on the rise and these are often complicated by concomitant hip fractures (1). Hip fractures—whose incidence increases with age—are not only common in the elderly (2) but are also predominatedapproximately 50%-by femoral neck fractures (FNFs) (3). Due to anatomical reasons, the femoral head becomes insufficiently supplied with blood after an FNF, which then leads to femoral head necrosis and bone non-union (4). Moreover, non-operative treatment requires long-term bed rest that often leads to various complications, and the 30-day mortality is between 5 and 10% (3). The standard treatment of elderly patients with FNFs is arthroplasty, which can achieve good results such as improved hip function, relief of hip pain, early ambulation, and return to independent living (5). Compared to total hip arthroplasty, hemiarthroplasty has the advantage of less trauma, shorter operation durations, less bleeding, and lower cost. This is suitable for elderly patients who generally are in a poor condition and unable to tolerate major surgery (6). Bipolar hemiarthroplasty is more commonly used in clinics than unipolar hemiarthroplasty, as the bipolar head increases the intra-articular mobility and reduces the relative movement between the prosthesis and acetabular cartilage and subchondral bone, which is expected to reduce the wear of acetabulum and prolong the life of the prosthesis (6, 7). Relatedly, elderly patients with FNFs who underwent bipolar hemiarthroplasty achieved a good clinical outcome, with a high rate of return to the pre-injury state, a great range of hip motion, and fast walking speed (8).

Today, the use of bone cement in bipolar hemiarthroplasty for the treatment of FNFs in elderly patients remains debatable

Frontiers in Medicine

(9, 10). Traditionally, cemented prostheses were mainly for elderly patients with poor bone quality (11). Indeed, as per the 2016 Dutch Orthopedic Association (DOV) guidelines, the preferred way to treat elderly patients with displaced FNFs is cemented hemiarthroplasty (12). Although cemented hemiarthroplasty results in better implant fixation, less implant-related complications, and better functional outcomes (13, 14), it is associated with a high risk of cardiovascular and respiratory complications such as myocardial infarction/arrhythmias and cardio-respiratory collapse due to cement-related toxicity and embolization of bone cement (15-17). On the other hand, uncemented hemiarthroplasty has short operation durations and low blood loss (18). Moreover, its use avoids bone cement implantation syndrome (BCIS) which increased perioperative mortalities (3)-the incidence of BCIS in cemented hemiarthroplasty ranged from 28 to 72% (16, 19). Due to variations in countries and regions, patient ethnic groups, and surgical techniques of operators, there is no consensus on these issues.

Most previous systematic reviews and meta-analyses on the comparison of cemented and uncemented hemiarthroplasty in the treatment of hip fractures included both unipolar and bipolar implants. Hence, this study aimed to comprehensively compare the effectiveness and safety of cemented bipolar hemiarthroplasty (CBH) and uncemented bipolar hemiarthroplasty (UCBH) for the treatment of FNFs in patients older than 60 years of age, *via* assessments of operation time, intra-operative blood loss, length of hospital stay, residual pain, re-operations, revisions, wound infections, prosthesis-related complications, general complications, and mortality.

2. Materials and methods

2.1. Search strategy

This study was designed and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (20). Two reviewers independently performed electronic searches of the PubMed, Web of Science, EMBASE, and

Abbreviations: FNFs, femoral neck fractures; CBH, cemented bipolar hemiarthroplasty; UCBH, uncemented bipolar hemiarthroplasty; RCTs, randomized controlled trials; WMD, weighted mean difference; OR, odds ration; DOV, Dutch Orthopedic Association; PRISMA, preferred reporting items for systematic reviews and meta-analyses; BCIS, bone cement implantation syndrome; ROB, cochrane risk of bias; NOS, Newcastle Ottawa scale; ASA, American Society of Anesthesiologists.

Cochrane Library database up to May 2022. The search consisted of terms relating to the condition including "hemiarthroplasty," "hemiprosthesis," "hemiarthroplasties," "replacement," "arthroplasty," "artificial femoral head replacement," "artificial femoral head arthroplasty," "bipolar," "cement," "cemented," "uncement," "uncemented," "cementless," "without bone cement," "non-cemented" (Supplementary Table 1). Moreover, we assessed the reference lists of relevant reviews to identify additional relevant studies. Any disagreements were resolved by a third author. The search was not restricted by language nor publication date. Finally, the systematic review and meta-analysis was registered on the PROSPERO website under the registration number CRD42021274253.

2.2. Inclusion and exclusion criteria

We enrolled randomized clinical trials (RCTs) and observational studies that met the following criteria: (1) the patients with FNFs were older than 60 years of age; (2) the intervention measures were either CBH or UCBH; (3) at least an outcome was reported and used for meta-analysis; (4) the presence of a comparison of outcomes between CBH and UCBH; (5) the full text was available. We excluded studies based on the following criteria: (1) the patients were younger than 60 years of age; (2) they were reviews, case reports, duplicates, conference abstracts; (3) they were basic research on animals or cadavers; (4) non-controlled studies; (5) we were unable to obtain the original text or extract accurate data; (6) they studied patients with a previous fracture in the same hip; (7) the patients with other pathological FNFs, such as tuberculosis, tumor, infection, and metabolic osteopathy.

2.3. Literature review

Two researchers independently searched for literature using the keywords and used the Endnote Document Management software to not only eliminate duplicated studies but also extract valid information *via* the literature titles and abstracts. After excluding articles as per the criteria, full texts were read to determine whether they met the inclusion criteria. Resultant studies were cross-checked and disagreements would be solved through discussion or decided by a third but senior researcher.

2.4. Data extraction

We extracted information using a pre-designed data extraction table. The following information was extracted by two independent researchers from the included studies: first author, publication date, country, study design, sample size, mean age, gender, surgical approach, type of intervention, type of prosthesis, American Society of Anesthesiologists (ASA) grade, follow-up period, and relevant clinical outcomes.

2.5. Outcome measures

We included studies reporting at least one of the following outcomes: operation time, intra-operative blood loss, length of hospital stay, residual pain, re-operation, revision, wound infection, mortality (perioperative period, postoperative a week, a month, 3 months, a year, and 2 years), complications related to prostheses such as dislocation, heterotrophic ossification, periprosthetic fracture, aseptic loosening of the prosthesis, subsidence of prosthesis (> 5 mm), intra-operative fracture and acetabulum erosion, general complications such as postoperative pulmonary infection, pulmonary embolism, urinary tract infection, deep venous thrombosis, decubitus, cardiovascular accidents (arrhythmia/myocardial infarction), and respiratory failure.

2.6. Quality assessment

Two researchers independently evaluated the quality of the RCTs and observational studies-disagreements were solved either through discussion or decided by the third senior researcher. The Cochrane Risk of Bias (ROB) assessment tool (21) was used to assess the quality of each RCT. The risk of bias was assessed from random sequence generation, concealment of the allocation sequence, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome, and selective reporting. The assessment for each entry involved answering a question, with either "yes"indicating low risk of bias-or "No"-indicating high risk of biasor "unclear"-indicating lack of information/uncertainty over the potential for bias (21). If all items were assessed with "Yes" then the quality grade was "A" which meant high quality. If one or more items were evaluated as "unclear" then the quality grade was "B" which meant moderate quality. If one or more items were evaluated as "No" then the quality grade was "C" which meant low quality. The Newcastle Ottawa scale (NOS) (22) was used to assess the quality of each observational study. Here, the risk of bias was assessed based on three essential domains which contained eight items (22): selection of the study subjects (4 points), comparability of groups (2 points), and ascertainment of the exposure or outcome (3 points). The highest score was 9, with higher scores indicating higher quality of included studies. Studies were classed as of high, moderate, and low quality when total scores were \geq 7, 4–6 and \leq 3 points, respectively.

2.7. Data synthesis and analysis

The Review Manager 5.3 software provided by the Cochrane Collaboration Network was used to perform a meta-analysis of comparable data. We calculated odds ratios (ORs) with a 95% confidence interval (CI) for dichotomous outcomes and weighted mean difference (WMD) with a 95% CI for continuous data. The heterogeneity among included studies was tested using the chi-square (χ^2) test and I-square (I²) tests (23), and P-value > 0.10 and an $I^2 \leq 50\%$ was considered insignificant heterogeneity. The fixedeffect model was used when there was insignificant heterogeneity between studies (P > 0.10, $I^2 \le 50\%$). Conversely, the randomeffect model was used when significant heterogeneity existed between studies ($P < 0.10, I^2 > 50\%$). Moreover, further sensitivity analyses were performed to investigate the potential origin of heterogeneity. Sensitivity analysis was conducted by omitting a study at a time and pooling the data from the remaining studies to explore possible sources of the high heterogeneity and determine the stability of the outcomes (9). Egger's test or funnel plots were used to estimate



publication bias when 10 or more studies were presented (24). The funnel plots were drawn in Review Manager 5.3 software and the Egger's test was performed in STATA 12 software at an alpha level of P < 0.05.

3. Results

3.1. Demographics and characteristics

249 articles were obtained in the preliminary election, 157 repeatedly published articles were eliminated by Endnote Document Management software, and 106 articles that obviously did not meet the inclusion criteria were eliminated after reading the title and abstract. After reading the full text of included studies and carrying out quality assessment, 37 unqualified articles were further removed, and 1 qualified literature was obtained by manual retrieval *via* assessing the reference lists of relevant reviews. Finally, 15 articles

were found to be eligible and included in the meta-analysis (25-39). Among them, 6 were RCTs (25-30) and 9 were observational studies (31-39). The PRISMA flow diagram showing the study selection process is shown in Figure 1.

Notably, there were 33,118 patients (33,127 hips) over 60 years old in the 15 included studies, which comprised 24,074 cases who underwent CBH and 9,053 cases who underwent UCBH. The characteristics of the included studies are summarized in Tables 1, 2. Although the study conducted by Langslet E et al. (26) was the same to that conducted by Figved W et al. (28), both studies were included because the follow-up time in the two studies was different, suggesting that there were some outcomes were different to be included. The follow-up time of the study conducted by Figved W et al. (28) was 12 months, however the follow-up time of the study conducted by Langslet E et al. (26) was prolonged to 60 months, therefore there was no duplicated data included in this meta-analysis. In addition, the number of patients was inconsistent with the number of operated hips in three studies (26, 28, 39) because some patients underwent bipolar hemiarthroplasty in both left and right hips at different time-points. Therefore, the mortality was calculated according to the number of patients whereas other outcomes were calculated according to the number of operated hips.

The Cochrane Collaboration's tool was used to assess the risk of bias in RTCs (21). We found that two studies had a quality grade of "A" (26, 28), three were "B" (25, 27, 30) and one was "C" (29). According to the Newcastle-Ottawa scale (NOS) (22), eight studies were classed as high quality (total scores \geq 7) (31, 33–39) and one study was classed as moderate quality (total scores between 4 and 6) (32). The summary of risk of bias scores in RCTs and observational studies are shown in Figures 2, 3 (Supplementary Tables 2, 3).

3.2. Meta-analysis results

3.2.1. Operation time

A total of seven studies reported the operation time, among which five were RCTs (25, 27-30) and two were observational studies (34, 37). A total of 1,258 cases were included in the analysis, 644 underwent CBH and 642 underwent UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.74). The fixed-effect model analysis revealed that the operation time was significantly shorter in the UCBH group relative to the CBH group [WMD = 13.01 min, 95% CI (10.79, 15.23), *P* < 0.00001; Figure 4].

3.2.2. Intra-operative blood loss

Six studies reported intra-operative blood loss, including four RCTs (21, 27, 28, 30) and two observational studies (34, 37). Pooled effect size of the six studies revealed significantly high heterogeneity $(I^2 = 62\%, P = 0.02)$, and a further sensitivity analysis indicated that the heterogeneity was caused by the study by Choi JY et al. (34). Thus, the study by Choi JY et al. (34) was excluded and then the fixed-effect model was employed to analyze the remaining studies. It was found that intra-operative blood loss was significantly lower in the UCBH group relative to the CBH group [WMD = 80.57 ml, 95% CI (61.14, 99.99), P < 0.00001; Figure 5], with no evidence of heterogeneity $(I^2 = 0\%, P = 0.89)$. Finally, 972 cases were included in the analysis, 476 underwent CBH and 496 underwent UCBH.

3.2.3. Length of hospital stay

A total of four studies reported the length of hospital stay, three were RCTs (28-30) and one was an observational study (38). The results comprised 586 cases, 288 underwent CBH and 298 underwent UCBH. There was no evidence of heterogeneity among the studies $(I^2 = 0\%, P = 0.81)$. The fixed-effect model analysis showed that there was no significant difference in the length of hospital stay between two groups [WMD = -0.30 days, 95% CI (-0.82, 0.23), P = 0.27; Figure 6].

3.2.4. Wound infections

Thirteen studies reported wound infections, four were RTCs (25, 26, 29, 30) and nine were observational studies (31-39). A total of 32,793 cases were included in the analysis, 23,912 underwent CBH and 8,881 underwent UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.61). Results of the fixed-effect model analysis showed that the incidence of wound infections in the CBH group was significantly lower relative to the UCBH group [OR = 0.80, 95% CI (0.68, 0.95), P = 0.01; Figure 7].

numbers)	НА	Female	46	87	117	87	40	24
Gender (υ	Male	33	25	45	25	13	ω
e (year)	UCHA		84 ± 4 (≥ 76)	83.0 ± 6.29 (≥ 70)	84.0 ± 5.1 (≥ 75)	83.0 ± 6.29 (≥ 70)	79.68 ± 8.62 (≥ 65)	79.6 ± 8 (61–96)
Mean age	CHA		86 ± 5 (≥ 76)	83.4 ± 5.68 (≥ 70)	84.3 ± 5.0 (≥ 75)	83.4 ± 5.68 (≥ 70)	82.09 ± 7.60 (≥ 65)	78 ± 7.2 (63-90)
of hips	UCHA		79	108	172	108	53	26
Number	СНА		79	112	162	112	53	27
^r patients	UCHA		79	105	172	105	53	26
Number of	СНА		79	108	162	108	53	27
Approach			Standard anterolateral approach	Posterior approach	I	Posterior approach	Lateral approach	I
Garden grade			III, IV	1	III, IV	1	I	I
Study period			2013.01-2015.12	2004.09-2006.08	2005-2010	2004.09-2006.08	2000.09-2001.12	1
Study type			RCT	RCT	RCT	RCT	RCT	RCT
Country			Slovenia	Norway	Norway	Norway	Italy	UK
References			Movrin I (25)	angslet E et al. (26)	falsnes O et al. (27)	igved W et al. (28)	Santini S et al. (29)	Emery RJ et al. (30)

FABL

TABLE 1 (Continued)

References	Country	Study type	Study period	Garden grade	Approach	Gender (r	numbers)		ASA (nı	umbers)		Impla	nt type	Follo	w-up
						UC	HA	C	HA	UC	HA	СНА	UCHA	CHA	UCHA
						Male	Female	I, II	III, IV	I, II	III, IV				
Movrin I (25)	Slovenia	RCT	2013.01-2015.12	III, IV	Standard anterolateral approach	31	48	40	39	46	33	Ecofit TM	Ecofit TM	3, 6, 12, and 24 months	3, 6, 12, and 24 months
Langslet E et al. (26)	Norway	RCT	2004.09–2006.08	-	Posterior approach	28	80	77	35	76	32	Spectron TM ; Smith and Nephew, Memphis, TN, USA	Corail TM ; DePuy/ Johnson and Johnson, Leeds, UK	60 months	60 months
Talsnes O et al. (27)	Norway	RCT	2005–2010	III, IV	-	37	135	68	94	68	104	Landos Titan, Depuy, Warshaw, IN, USA	Landos Corail, Depuy, Warshaw, IN, USA	12 months	12 months
Figved W et al. (28)	Norway	RCT	2004.09–2006.08	-	Posterior approach	28	80	77	35	76	32	Spectron TM ; Smith and Nephew, Memphis, TN, USA	Corail TM ; DePuy/ Johnson and Johnson, Leeds, UK	1 week; 1, 3, 12, and 24 months	1 week; 1, 3, 12, and 24 months
Santini S et al. (29)	Italy	RCT	2000.09-2001.12	-	Lateral approach	11	42	22	31	26	27	-	-	6 and 12 months	6 and 12 months
Emery RJ et al. (30)	UK	RCT	-	-	-	4	22	-	-	-	-	Thompson, Johnson and Johnson, England	Austin Moore, Johnson and Johnson, England	Mean: 17 months Range: 12 to 27 months	Mean: 18 months Range: 12 to 30 months

RCT, randomized controlled trial; CHA, cemented bipolar hemiarthroplasty; UCHA, uncemented bipolar hemiarthroplasty; ASA, American Society of Anesthesiologists.

TABLE 2 Baseline characteristics of observational studies included in review.

References	Country	Study type	Study period	Garden	Approach	Number o	of patients	Numbe	r of hips	Mean a	ge (year)	Gender (numbers)
				grade		СНА	UCHA	CHA	UCHA	CHA	UCHA	CI	HA
												Male	Female
Kristensen TB et al. (31)	Norway	Observational study	2005.01-2017.12	III, IV	Anterior, lateral, and posterior approach	22639	7539	22639	7539	84±6 (≥70)	84±6 (≥70)	6339	16300
Song JSA et al. (32)	Canada	Observational study	2010.01-2016.05	-	-	361	296	361	296	81.4 (≥ 65)	80.3 (≥ 65)	88	273
Rai SK et al. (33)	Indian	Observational study	2013.01-2015.07	-	posterior approach	42	42	42	42	79.5 ± 5.04 (≥ 65)	75.9 ± 4.04 (≥ 65)	16	26
Choi JY et al. (34)	Korea	Observational study	2009.03-2015.02	III, IV	Modified Hardinge approach	115	65	115	65	77 (≥ 65)	76 (≥ 65)	31	84
Khorami M et al. (35)	Iran	Observational study	2011.01-2015	-	-	22	29	22	29	79 (70–92)	71.7 (65–76)	2	20
Cicek H et al. (36)	Turkey	Observational study	2007–2012	-	Posterolateral approach	43	41	43	41	75. \pm 17.78 (\geq 70)	$77.5 \pm 13.75 \\ (\geq 70)$	20	23
Ng and Krishna (37)	Singapore	Observational study	2005.01-2009.12	-	-	96	111	96	111	73 (60–91)	72 (60–87)	21	75
Viberg B et al. (38)	Denmark	Observational study	1991–1998	-	-	209	360	209	360	83 (79–88)	84 (80–89)	40	169
Lo WH et al. (39)	China	Observational study	1985.10-1990.07	-	Anterolateral or Moore's approach	113	131	114	132	65-93	62-94	-	-

(Continued)

TABLE 2 (Continued)

References	Country	Study type	Study period	Garden grade	Approach	Gender	(numbers)		ASA (ทเ	umbers)		Impla	ant type	Follo	ow-up
						U	СНА	С	HA	UC	СНА	СНА	UCHA	CHA	UCHA
						Male	Female	I, II	III, IV	I, II	III, IV				
Kristensen TB et al. (31)	Norway	Observational study	2005.01–2017.12	III, IV	Anterior, lateral, and posterior approach	2262	5277	7754	14885	2731	4808	Various types	Various types	Median: 24 months Interquartile range: 6 to 50.4 months	Median: 24 months Interquartile range: 6 to 50.4 months
Song JSA et al. (32)	Canada	Observational study	2010.01-2016.05	-	-	88	208	107	221	81	179	-	-	12 months	12 months
Rai SK et al. (33)	Indian	Observational study	2013.01-2015.07	-	posterior approach	19	23	-	-	-	-	Modular®	Modular®	Mean: 18.07 months Range: 6 to 30 months	Mean: 18.07 months Range: 6 to 30 months
Choi JY et al. (34)	Korea	Observational study	2009.03-2015.02	III, IV	Modified Hardinge approach	19	46	-	-	-	-	Various types	Various types	Mean: 28 months Arange: 6 to 73 months	Mean: 26 month Arange: 6 to 71 months
Khorami M et al. (35)	Iran	Observational study	2011.01-2015	-	-	17	12	-	-	-	-	Zimmer	Zimmer	Mean: 18.9 months Arange: ≥ 6 months	Mean: 19.5 months Arange: ≥ 6 months
Cicek H et al. (36)	Turkey	Observational study	2007–2012	-	Posterolateral approach	18	23	0	43	0	41	Corin® TaperFit	Corin [®] MetaFix	Mean: 44.8 months Range: 29 to 59 months	Mean: 47.4 months Range: 31 to 58 months
Ng and Krishna (37)	Singapore	Observational study	2005.01-2009.12	-	-	25	86	-	-	-	-	-	-	Mean: 28.8 months Range: 24 to 50.4 months	Mean: 28.8 months Range: 24 to 50.4 months
Viberg B et al. (38)	Denmark	Observational study	1991–1998	-	-	70	290	-	-	-	-	Ultima	Charnley- Hastings, Furlong	Range: 144 to 228 months	Range: 144 to 228 months
Lo WH et al. (39)	China	Observational study	1985.10–1990.07	-	Anterolateral or Moore's approach	-	-	-	-	-	-	Bateman	Bateman	Mean: 34 months Range: ≥ 24 months	Mean: 34 month Range: ≥ 24 months

CHA, cemented bipolar hemiarthroplasty; UCHA, uncemented bipolar hemiarthroplasty; ASA, American Society of Anesthesiologists.



Risk of bias assessment of randomized controlled trials



3.2.5. Residual pain

Three studies reported residual pain, one was RCT (28, 30) and two were observational studies (31, 39). In total of 12,589 cases were included in the analysis, 9,311 underwent CBH and 3,728 underwent UCBH. The pooled effect size analysis of the three studies revealed significantly high heterogeneity ($I^2 = 86\%$, P = 0.11). Next, the studies were analyzed with the random-effect model which found no significant difference between CBH group and UCBH group [OR = 0.36, 95% CI (0.13, 1.03), P = 0.06; Figure 8].

3.2.6. Revisions

Four studies reported revisions, one was RCT (28) and three were observational studies (36-38). Pooled effect size of the four studies showed that there was high heterogeneity ($I^2 = 62\%$, P = 0.05). Further sensitivity analysis showed that the high heterogeneity was from the study by Viberg B et al. (38). When the study by Viberg B et al. (38) was excluded, the fixed-effect model analysis revealed no significant difference in revision rates between two groups [OR = 3.13, 95% CI (0.91, 10.70), *P* = 0.07; Figure 9], and there was no significant heterogeneity ($I^2 = 15\%$, P = 0.31). Finally, 511 cases were included in the analysis, 251 underwent CBH and 260 underwent UCBH.

3.2.7. Re-operations

Five studies reported re-operations, one was RCT (26) and four were observational studies (31, 32, 34, 39). A total of 31,804 cases were included in the analysis, 23,436 underwent CBH and 8,368 underwent UCBH. There was no significant heterogeneity among the studies $(I^2 = 21\%, P = 0.28)$. The fixed-effect model analysis showed that the re-operation rates was significant lower in the CBH group than in the UCBH group [OR = 0.61, 95% CI (0.54, 0.68), P < 0.00001; Figure 10].

3.2.8. Complications related to prosthesis 3.2.8.1. Prosthesis dislocation

Eight studies reported prosthesis dislocation, three were RCTs (25, 26, 29) and five were observational studies (31, 33, 35, 38, 39). A total of 31,612 cases were included in the analysis, 23,270 underwent CBH and 8,342 underwent UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.98). The fixedeffect model analysis showed that there was no significant difference in the incidence of prosthesis dislocation between the two groups [OR = 0.83, 95% CI (0.67, 1.04), *P* = 0.11; Figure 11].

3.2.8.2. Intra-operative fractures

Five studies reported intra-operative fractures, three were RCTs (25, 28, 29) and two were observational studies (35, 37). A total of 742 cases were included in the analysis, 362 underwent CBH and 380 underwent UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.96). Results of the fixed-effect model analysis showed that the incidence of intra-operative fractures in the CBH group was significantly lower compared with the UCBH group [OR = 0.24, 95% CI (0.07, 0.86), *P* = 0.03; Figure 12].

3.2.8.3. Periprosthetic fractures

Six studies reported periprosthetic fractures, two were RCTs (25, 26) and four were observational studies (31, 32, 37, 38). A total of 31,611 cases were included in the analysis, 23,496 underwent CBH and 8,439 UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.62). Results of the fixed-effect model analysis showed that the incidence of periprosthetic fractures in the CBH group was significantly lower compared with the UCBH group [OR = 0.24, 95% CI (0.18, 0.31), *P* < 0.00001; Figure 13].

3.2.8.4. Aseptic loosening of prosthesis

Five observational studies reported aseptic loosening of prosthesis (31, 33, 36, 38, 39), and there was high heterogeneity

	Ce	mented	1	Unce	emente	ed		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Choi JY 2016	104	17	115	93	18	93	21.4%	11.00 [6.20, 15.80]	
Emery RJH 1991	70	19.8	27	62	16.6	26	5.1%	8.00 [-1.82, 17.82]	
Figved W 2009	82.6	19.8	112	70.3	19.3	108	18.4%	12.30 [7.13, 17.47]	_
Movrin I 2020	67	18	79	51	16	79	17.5%	16.00 [10.69, 21.31]	
Ng ZD 2014	95	18	96	81	18	111	20.4%	14.00 [9.08, 18.92]	
Santini S 2005	75	22.43	53	56.98	55	53	1.9%	18.02 [2.03, 34.01]	
Talsnes O 2012	84	30	162	71	22	172	15.3%	13.00 [7.33, 18.67]	
Total (95% CI)			644			642	100.0%	13.01 [10.79, 15.23]	•
Heterogeneity: Chi ² =	: 3.50. df	= 6 (P =	0.74);	l ² = 0%					
Test for overall effect	: Z = 11.4	9 (P < 0).00001	D					-20 -10 0 10 20
									Favours (Cemented) Favours (Uncemented)

Forest plot for comparison of operation time between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



FIGURE 5

Forest plot for comparison of intra-operative blood loss between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



(UCBH) group

among the five studies as determined by the pooled effect size $(I^2 = 53\%, P = 0.08)$. Further sensitivity analysis revealed that the high heterogeneity was caused by the study by Cicek H et al. (36). When the study by Cicek H et al. (36) was excluded, the remaining articles were analyzed with the fixed-effect model which showed that the incidence of aseptic loosening of prosthesis was significantly lower in the CBH group compared with the UCBH group [OR = 0.20, 95% CI (0.09, 0.44), P < 0.00001; Figure 14], and there was no evidence of heterogeneity ($I^2 = 0\%$, P = 0.59). Finally, 31,077 cases included in this analysis, 23,004 underwent CBH and 8,073 underwent UCBH.

3.2.8.5. Subsidence of prosthesis (>5 mm)

Three observational studies reported the subsidence of prosthesis (> 5 mm) (34, 36, 39), the pooled effect size of the three studies revealed significantly high heterogeneity ($I^2 = 73\%$, P = 0.08), and a further sensitivity analysis showed that the heterogeneity originated from the study by Lo WH et al. (39). After excluding the study by Lo WH et al. (39), the remaining studies were analyzed with the fixed-effect model which revealed no significant difference in the incidence of subsidence of prosthesis (> 5 mm) between the two groups [OR = 4.09, 95% CI (0.68, 24.46), P = 0.12; Figure 15], and there was no significant heterogeneity ($I^2 = 0\%$, P = 1.00). Finally, 264 cases were included in the analysis, 158 underwent CBH and 106 underwent UCBH.

3.2.8.6. Acetabulum erosion

Two studies reported acetabulum erosion, one study was RCT (26) and another was an observational study (39). A total of 466 cases were included in the analysis, 226 underwent CBH and 240 underwent UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.47). The fixed-effect model analysis showed there was no significant difference in the incidence of acetabulum erosion between the two groups [OR = 0.93, 95% CI (0.52, 1.65), P = 0.80; Figure 16].

						outo rutto			
Study or Subgroup	Events	lotal	Events	lotal	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% C	<u> </u>
Choi JY 2016	0	115	3	65	1.6%	0.08 [0.00, 1.52]			
Cicek H 2015	2	43	1	41	0.3%	1.95 [0.17, 22.38]		·	
Emery RJH 1991	1	27	0	26	0.2%	3.00 [0.12, 77.03]			
Khorami M 2016	1	22	1	29	0.3%	1.33 [0.08, 22.57]			
Kristensen TB 2020	425	22639	179	7539	93.3%	0.79 [0.66, 0.94]			
Langslet E 2013	4	112	1	108	0.3%	3.96 [0.44, 36.04]			
Lo WH 1994	1	114	2	132	0.7%	0.58 [0.05, 6.43]			-
Movrin I 2020	3	79	0	79	0.2%	7.27 [0.37, 143.19]			
Ng ZD 2014	2	96	3	111	1.0%	0.77 [0.13, 4.68]			
Rai SK 2017	1	42	2	42	0.7%	0.49 [0.04, 5.59]			
Santini S 2005	1	53	0	53	0.2%	3.06 [0.12, 76.76]			
Song JSA 2019	1	361	0	296	0.2%	2.47 [0.10, 60.79]			
Viberg B 2013	0	209	4	360	1.2%	0.19 [0.01, 3.53]	-		
Total (95% CI)		23912		8881	100.0%	0.80 [0.68, 0.95]		•	
Total events	442		196						
Heterogeneity: Chi ² = 1	10.11. df=	= 12 (P =	: 0.61); ² =	: 0%			+	<u> </u>	- <u>t</u> t

Forest plot for comparison of wound infections between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



FIGURE 8

Forest plot for comparison of residual pain at last follow-up between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



Forest plot for comparison of revision rate between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group

3.2.8.7. Heterotopic ossification

Two observational studies reported heterotopic ossification (36, 39). The studies comprised 330 cases, 157 underwent CBH and 172 underwent UCBH. There was no evidence of heterogeneity among the studies ($I^2 = 0\%$, P = 0.58). The fixed-effect model for analysis showed that the incidence of heterotopic ossification in the CBH group was higher compared with the UCBH group [OR = 2.07, CI (1.14, 3.78), *P* = 0.02; Figure 17].

3.2.9. General complications

The pooled effect analysis showed no evidence of heterogeneity $(I^2 = 0\%, P = 0.97)$ among the studies in terms of pulmonary

pulmonary embolisms, urinary tract infections, infections, cardiovascular accidents (arrhythmia/myocardial infarction), respiratory failure, and deep venous thromboses. In addition, there was no significant difference in the incidence of pulmonary infections [OR = 0.54, CI (0.21, 1.39), P = 0.20; $I^2 = 0\%$, P = 0.82], pulmonary embolisms [OR = 2.67, CI (0.72, 9.87), P = 0.14; $I^2 = 0\%$, *P* = 0.81], urinary tract infections [OR = 0.76, CI (0.34, 1.70), *P* = 0.50; $I^2 = 0\%$, P = 0.89], decubitus [OR = 1.05, CI (0.35, 3.18), P = 0.93; $I^2 = 0\%$, P = 0.48], cardiovascular accidents (arrhythmia/myocardial infarction) [OR = 1.62, CI (0.69, 3.82), P = 0.27; $I^2 = 0\%$, P = 0.67], respiratory failure [OR = 1.77, CI (0.26, 11.89), P = 0.56; $I^2 = 0\%$, P = 0.58], and deep venous thromboses [OR = 0.73, CI (0.19, 2.84),



Forest plot for comparison of re-operation rates between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



Forest plot for comparison of prosthesis dislocations between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.

	Cemen	ted	Unceme	ented		Odds Ratio		Odds	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	d, 95% Cl		
Figved W 2009	1	112	2	108	16.6%	0.48 [0.04, 5.34]					
Khorami M 2016	0	22	4	29	31.4%	0.13 [0.01, 2.47]			<u> </u>		
Movrin I 2020	0	79	2	79	20.4%	0.19 [0.01, 4.13]					
Ng ZD 2014	0	96	1	111	11.4%	0.38 [0.02, 9.48]		•			
Santini S 2005	0	53	2	53	20.3%	0.19 [0.01, 4.11]					
Total (95% CI)		362		380	100.0%	0.24 [0.07, 0.86]					
Total events	1		11								
Heterogeneity: Chi ² =	:0.61,df=	4 (P =	0.96); l ² =	0%			-+			40	400
Test for overall effect	: Z = 2.20 (P = 0.0)3)				0.01	U.I	 	10	100
			·					Favours [Cemented]	Favours [Uncerner	rteaj

Forest plot for comparison of intra-operative fractures between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.

 $P = 0.65; I^2 = 0\%, P = 0.65$] between the two groups. The incidence of general complications was not significantly different between the two groups [OR = 1.04, CI (0.70, 1.53), P = 0.84; $I^2 = 0\%$, P = 0.97; Figure 18].

3.2.10. Mortality

The pooled effect analysis showed that perioperative mortality (within 72 h) [OR = 2.39, CI (1.71, 3.32), P < 0.00001; $I^2 = 0\%$, P = 0.95] and 1-week mortality postoperatively [OR = 1.22, CI $(1.05, 1.41), P = 0.008; I^2 = 0\%, P = 0.49$ in the CBH group were significantly lower compared with those in the UCBH group. There were no significant differences in 1-month mortality post-operatively $[OR = 1.07, CI (0.98, 1.18), P = 0.14; I^2 = 43\%, P = 0.18], 3$ -month

mortality post-operatively [OR = 0.90, CI (0.44, 1.84), P = 0.78; $I^2 = 0\%$, P = 0.60], 1-year mortality post-operatively [OR = 0.96, CI $(0.90, 1.01), P = 0.14; I^2 = 14\%, P = 0.32]$, and 2-year mortality postoperatively [OR = 0.87, CI (0.57, 1.33), P = 0.52; $I^2 = 0\%$, P = 0.59] between the two groups (Figure 19).

3.3. Heterogeneity and sensitivity analysis

The results of heterogeneity and sensitivity analyses demonstrated high heterogeneity in the indicators such as intraoperative blood loss, residual pain, revision, aseptic loosening of prosthesis, subsidence of prosthesis (> 5 mm), and 1-year mortality. Further sensitivity analysis showed that there were no significant

Study or Subgroup	Evonte	Total	Evonte	Total	Mojaht	M H Eived 05% Cl	M H Eived 05% Cl
Study of Subgroup	Lvents	Total	Lvents	Total	weight	M-11, 11Aeu, 35% CI	M-H, HACU, 55% CI
Kristensen TB 2020	53	22639	88	7539	66.4%	0.20 [0.14, 0.28]	• • • • • • • • • • • • • • • • • • •
Langslet E 2013	1	112	8	108	4.1%	0.11 [0.01, 0.92]	
Movrin I 2020	1	79	2	79	1.0%	0.49 [0.04, 5.56]	
Ng ZD 2014	0	96	1	111	0.7%	0.38 [0.02, 9.48]	· · · · · · · · · · · · · · · · · · ·
Song JSA 2019	14	361	34	296	18.1%	0.31 [0.16, 0.59]	_ _
Viberg B 2013	6	208	27	360	9.7%	0.37 [0.15, 0.90]	
Total (95% CI)		23495		8493	100.0%	0.24 [0.18, 0.31]	◆
Total events	75		160				
Heterogeneity: Chi ² = 1	3.52, df =	5 (P = 0.	62); I^z = 0	%			

Forest plot for comparison of periprosthetic fractures between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



FIGURE 14

Forest plot for comparison of aseptic loosening of prosthesis between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.

	Cemen	ited	Uncerne	nted		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Choi JY 2016	3	115	0	65	36.0%	4.08 [0.21, 80.14]	
Cicek H 2015	4	43	1	41	64.0%	4.10 [0.44, 38.35]	
Lo WH 1994	4	114	19	132	0.0%	0.22 [0.07, 0.66]	
Total (95% CI)		158		106	100.0%	4.09 [0.68, 24.46]	
Total events	7		1				
Heterogeneity: Tau ² =	= 0.00; Ch	i² = 0.0	0, df = 1 (F	= 1.00)	; I ² = 0%		
Test for overall effect	Z=1.54	(P = 0.1	2)				Favours [Cemented] Favours [Uncemented]

FIGURE 15

Forest plot for comparison of subsidence of prosthesis (>5 mm) between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



FIGURE 16

Forest plot for comparison of acetabulum erosions between cemented bipolar hemiarthroplasty (CBH) group and uncemented bipolar hemiarthroplasty (UCBH) group.



changes in the results, indicating that the heterogeneity had little influence on results and the findings were relatively reliable.

3.4. Publication bias

We constructed the funnel plot and Egger's test for wound infections to explore the level of publication bias. Analysis of the funnel plot showed that the scatter plot was symmetrical indicating that the level of publication bias was low (Figure 20). In addition, the Egger's test revealed that there was no evidence of publication bias in wound infections data among studies (P = 0.351) (Figure 21).

4. Discussion

Due to increased life expectancy and the resultant large elderly population, the incidence of femoral neck fractures (FNFs) is on the rise (1) as elderly patients are prone to FNFs after falling-such fractures heal slowly due to unique anatomy (4). With the continuous improvement of surgical technology, hemiarthroplasty has been successfully used to treat elderly patients ailing from FNFs. This effectively reduced the incidence of complications -such as urinary tract infection, decubitus, deep venous thrombosis, and hypostatic pneumonia-caused by long-term bed rests following traditional treatments (3). A bipolar head has double-action features-the joint activity is concurrently operated by both internal and external joints-which not only reduced the wear of the acetabulum but also greatly extended the service life of the prosthesis (6, 7). A meta-analysis showed the rate of acetabular erosion in bipolar hemiarthroplasty was significantly lower than that in unipolar hemiarthroplasty (1.2 and 5.5%, respectively), yet the other compared outcomes showed no significant difference between two groups (8). Bipolar hemiarthroplasty remains the main current surgical method for the treatment of FNFs in the elderly. Furthermore, the use of cemented or non-cemented prostheses in treating FNFs in elderly patients remains debatable. Most meta-analyses that compared cemented and uncemented hemiarthroplasty in treating FNFs included both bipolar and unipolar head prostheses. Therefore, our meta-analysis compared the effectiveness and safety between cemented and uncemented hemiarthroplasty for the treatment of FNFs in elderly patients only for bipolar head prostheses. Elmenshawy AF et al. (10) compared cemented bipolar hemiarthroplasty (CBH) and uncemented bipolar hemiarthroplasty (UCBH) for FNFs treatment in the elderly, but the included literature which were published before 2014. Another meta-analysis compared CBH and UCBH was for the treatment of unstable intertrochanteric fractures (9).

We found that CBH associated with longer operation time, considering the reasons was that the cemented hemiarthroplasty need to prepare and place the bone cement, as well as waiting for the cement to set. In theory, the prolonged operation time may result in increasing intra-operative blood loss during operation, this hypothesis was consistent with our result that CBH associated with more intra-operative blood loss in comparison to UCBH. The other reason was that this higher intra-operative bleeding may in CBH also result from repeated reaming during operation that results in increasing intramedullary hemorrhage. However, intra-operative blood loss from cemented and uncemented hemiarthroplasty did not significantly differ in a previous meta-analysis as although cemented hemiarthroplasty had longer operation durations, the bone cement immediately closed the medullary cavity, thus reducing intra-operative blood loss (40). Kong XG (41) found that postoperative hospital stays were shorter for patients who underwent cemented hemiarthroplasty than uncemented hemiarthroplasty. He hypothesized that a cemented prosthesis achieves good stability in the early postoperative period, since bone cement fixation filled the gap between the trabecular bone and prosthesis with bone cement, creating a micro internal locking fixation at the interface of bonebone cement-prosthesis after bone cement setting. Early stabilization of cemented prostheses promoted early out-of-bed activities and fast recoveries, which ultimately shortened postoperative hospital stays. Uncemented prostheses mainly depend on the growth of the bone tissue into the prosthesis to form a close biological fixation between bone and prosthesis surfaces, however, this takes long durations and has poor early stability (41). Since elderly patients often have a degree of osteoporosis, those with uncemented hemiarthroplasty should postpone the full weight-bearing time to avoid sinking the biological femoral stem. Our meta-analysis showed there was no significant difference in postoperative hospital stays between patients who had underwent CBH and UCBH procedures.

Surgical wound infection is a tabooed complication for surgeons, and increased operation time theoretically increase the risk of wound infection. There was a lower association with the incidence of wound infections for CBH than UCBH as per our meta-analysis which had a pooled effect size of 13 studies and no significant publication bias (Egger's test, P = 0.351). Wound infection included superficial and deep infection. Four studies reported deep wound infections (25, 26, 29, 39), two reported superficial wound infections (30–38). Therefore, these were all summarized as wound infections in the meta-analysis. Deep wound infection following hip arthroplasty was a disastrous

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	
Emery RJH 1991 3 27 3 26 5.4% 0.96 [0.18, 5.24] Figred W 2009 2 112 3 108 6.0% 0.64 [0.10, 3.88] Khorami M 2016 0 22 1 29 2.5% 0.42 [0.02, 10.87] Ng ZD 2014 1 96 2 111 3.7% 0.57 [0.05, 6.43] Subtotal (95% CI) 372 339 24.0% 0.54 [0.21, 1.39] Total events 6 11 Heterogeneity: Chi ² = 1.54, df = 4 (P = 0.82); P = 0% Test for overall effect Z = 1.28 (P = 0.20) 1.62 Pulmonary embolisms Chol JY 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cicek H 2015 2 43 1 41 2.0% 1.96 [0.24, 113.59] Lo WH 1991 2 27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 6.59 [0.28, 23.84] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ² = 0.98, df = 3 (P = 0.81); P = 0% Test for overall effect Z = 1.47 (P = 0.14) 1.16.3 Uniary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 2.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.68 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.69) 1.64 Decubius Emery RJH 1991 1 2.7 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Samtini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93	
Figure W 2009 2 112 3 108 6.0% 0.64 [0.10, 3.88] Khorami M 2016 0 22 1 29 2.5% 0.42 [0.02, 10.87] Ng ZD 2014 1 96 2 111 3.7% 0.57 [0.05, 6.4] Subtotal (95% CI) 372 339 24.0% 0.54 [0.21, 1.39] Total events 6 11 Heterogeneihy: Chl ^P = 1.54, df = 4 ($P = 0.82$); $P = 0\%$ Test for overall effect Z = 1.28 ($P = 0.82$); $P = 0\%$ Test for overall effect Z = 1.28 ($P = 0.82$); $P = 0\%$ Test for overall effect Z = 1.28 ($P = 0.82$); $P = 0\%$ Test for overall effect Z = 1.27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1994 2 27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.89 [0.28, 123.94] Subtotal (95% CI) 299 264 5.3% 2.67 [0.72, 9.87] Total events 8 8 2 Heterogeneihy: Chl ^P = 0.98, df = 3 ($P = 0.81$); $P = 0\%$ Test for overall effect Z = 1.47 ($P = 0.14$) 1.63.0 Unitary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneihy: Chl ^P = 0.62, df = 3 ($P = 0.89$); $P = 0\%$ Test for overall effect Z = 0.89 ($P = 0.50$) 1.64. Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneihy: Chl ^P = 1.49, df = 2 ($P = 0.48$); $P = 0\%$ Test for overall effect Z = 0.09 ($P = 0.93$) Heterogeneihy: Chl ^P = 1.49, df = 2 ($P = 0.48$); $P = 0\%$ Test for overall effect Z = 0.99 ($P = 0.93$) Heterogeneihy: Chl ^P = 1.49, df = 2 ($P = 0.48$); $P = 0\%$ Test for overall effect Z = 0.09 ($P = 0.93$)	
Khorami M 2016 0 22 1 29 2.5% 0.42 [0.02, 10.87] Ng ZD 2014 1 96 2 111 3.7% 0.57 [0.05, 6.43] Subtotal (95% CI) 372 339 24.0% 0.57 [0.05, 6.43] Total events 6 11 Heterogeneity: Chi ^P = 1.54, df = 4 (P = 0.82); P = 0% Test for overall effect Z = 1.28 (P = 0.20) 1.62 Pulmonary embolisms Chol JY 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cicek H 2015 2 43 1 441 2.0% 1.95 [0.17, 22.38] Emery RJH 1991 2 27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1934 2 114 0 132 0.9% 5.69 [0.28, 123.94] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ^P = 0.98, df = 3 (P = 0.81); P = 0% Test for overall effect Z = 1.47 (P = 0.14) 1.6.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 16% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Sathotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ^P = 0.62, df = 3 (P = 0.99); P = 0% Test for overall effect Z = 0.68 (P = 0.50) 1.6.4 Decubius Emery RJH 1931 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Sathotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi ^P = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.39); P = 0% Test for overall effect Z = 0.09 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) 4.65 P = 0.48, df = 2 P = 0.48; P = 0 %	
Ng ZD 2014 1 96 2 111 3.7% 0.57 [0.05, 6.43] Total events 6 11 Heterogeneity, Ch ² = 1.54, df = 4 (P = 0.82), P = 0% Test for overall effect Z = 1.28 (P = 0.82), P = 0% Test for overall effect Z = 1.28 (P = 0.20) 1.62 Pulmonary embolisms Chol JV 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cicek H 2015 2 43 1 41 2.0% 1.95 [0.17, 22.38] Emery RJH 1991 2 27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.20 [0.24, 113.59] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 $g = 2.8$ Heterogeneity, Ch ² = 0.98, df = 3 (P = 0.81); P = 0% Test for overall effect Z = 1.47 (P = 0.14) 1.6.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 1111 7.3% 0.57 [0.10, 3.18] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity, Ch ² = 0.68 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.50) 1.6.4 Hore overall effect Z = 0.68 (P = 0.50) 1.6.4 Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity, Ch ² = 1.49, df = 2 (P = 0.46); P = 0% Test for overall effect Z = 0.09 (P = 0.93) H 4 5.6 Contained and con	
Subtotal (95% CI) 372 339 24.0% 0.54 [0.21, 1.39] Total events 6 11 Heterogeneity: $Chi^{2} = 1.54$, $df = 4$ (P = 0.82); P = 0% Test for overall effect Z = 1.28 (P = 0.20) 1.6.2 Pulmonary embolisms Choi JV 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cicek H 2015 2 43 1 41 2.0% 1.95 [0.17, 22.38] Emery RJH 1991 2 27 0 26 0.9% 6.20 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.28 [0.28, 123.94] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ² = 0.88, df = 3 (P = 0.81); P = 0% Test for overall effect Z = 1.47 (P = 0.14) 1.6.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.68 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.50) 1.6.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.8% 1.76 [0.29, 10.75] Santini S 2005 2 63 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) 4.45 E Condianced considence (output heriscipus event of a life output in the	
Total events $11 - 22 = 1.28 (P = 0.82); P = 0\%$ Test for overall effect: $Z = 1.28 (P = 0.20)$ 1.16.2 Pulmonary embolisms Choi JY 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cleck H 2015 2 43 1 41 2.0% 1.96 [0.17, 22.38] Emery RJH 1991 2 27 0 26 0.9% 5.29 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.29 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.89 [0.28, 123.94] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ^P = 0.89, df = 3 (P = 0.81); P = 0% Test for overall effect: $Z = 1.47 (P = 0.14)$ 1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ^P = 0.62, df = 3 (P = 0.89); P = 0% Test for overall effect: $Z = 0.68 (P = 0.50)$ 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ^P = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect: $Z = 0.69 (P = 0.93)$ 1.46.6 Conditione consident of (whethetic hemester in a bit for ext in a bit for a bit over a bit of (0, 2.77, 0.3] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ^P = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect: $Z = 0.09 (P = 0.93)$ 1.46.6 Conditione consident of (other themester in a bit protect in a bit over a bit of (0, P = 0.93) 1.46.6 Conditione consident of (other themester in a bit protect in a bit over a bit of (0, P = 0.93) 1.46.7 Conditione consident of (other themester in a bit over a bit of (0, P = 0.93)	
The theorem is a second second and the second in the second in the second in the second seco	
1.16.2 Pulmonary embolisms Choi JY 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cicek H 2015 2 43 1 41 2.0% 1.95 [0.17, 22.38] Emery RJH 1991 2 27 0 26 0.9% 5.29 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 6.39 [0.28, 123.94] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ² = 0.98, df = 3 (P = 0.81); P = 0% Test for overall effect: Z = 1.47 (P = 0.14) 1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1.9 1.6.8% 1.33 [0.08, 22.57] 1.0.8 1.33 [0.08, 22.67] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4 1.0.4	
Choi JY 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74] Cicek H 2015 2 43 1 41 2.0% 1.95 [0.17, 22.38] Emery RUH 1991 2 2.7 0 26 0.9% 5.29 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.29 [0.28, 123.94] Subtotal (95% Cl) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ^P = 0.98, df = 3 (P = 0.81); I ^P = 0% Test for overall effect: $Z = 1.47$ (P = 0.14) 1.16.3 Urinary tract infections Emery RUH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ^P = 0.62, df = 3 (P = 0.89); I ^P = 0% Test for overall effect: $Z = 0.68$ (P = 0.50) 1.16.4 Decubitus Emery RUH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ^P = 1.49, df = 2 (P = 0.48); I ^P = 0% Test for overall effect: $Z = 0.09$ (P = 0.93) 1.16.4 Decubitus Emery RUH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ^P = 1.49, df = 2 (P = 0.48); I ^P = 0% Test for overall effect: $Z = 0.09$ (P = 0.93) 1.16 Condimended to excident of carb drame between sticl information	
Cicek H 2015 2 43 1 41 2.0% 1.95 [0.17, 22.38] Emery RJH 1991 2 27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.80 [0.28, 123.94] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ² = 0.98, df = 3 (P = 0.81); P = 0% Test for overall effect Z = 1.47 (P = 0.14) 1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.68 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.50) 1.16.4 Decubius Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) 4.45 E Cordin executes consider to consider the proceedial information:	
Emery RJH 1991 2 27 0 26 0.9% 5.20 [0.24, 113.59] Lo WH 1994 2 114 0 132 0.9% 5.89 [0.28, 123.94] Subtotal (95% CI) 299 264 6.3% 2.67 [0.72, 9.87] Total events 8 2 Heterogeneity: Chi ² = 0.98, df = 3 (P = 0.81); P = 0% Test for overall effect Z = 1.47 (P = 0.14) 1.63. Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.67] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); P = 0% Test for overall effect Z = 0.68 (P = 0.50) 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect Z = 0.09 (P = 0.93) 1.465 Cordin executed consider the constant executed in infected in the constant executed in the constant e	
Low mass of the second	
Total events 8 2 Heterogeneity: $Chi^2 = 0.98$, $df = 3$ ($P = 0.81$); $ F = 0\%$ Test for overall effect: $Z = 1.47$ ($P = 0.14$) 1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.67] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santhi S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: $Chi^2 = 0.62$, $df = 3$ ($P = 0.89$); $ P = 0\%$ Test for overall effect: $Z = 0.68$ ($P = 0.50$) 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.76] Santhi S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: $Chi^2 = 1.49$, $df = 2$ ($P = 0.48$); $ P = 0\%$ Test for overall effect: $Z = 0.09$ ($P = 0.93$) 1.46 E Cardia provide a contraction for example interpreted intiferentiation	
Heterogeneily: $Chi^2 = 0.98$, $df = 3$ (P = 0.81); $l^2 = 0\%$ Test for overall effect $Z = 1.47$ (P = 0.14) 1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santhi IS 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: $Chi^2 = 0.62$, $df = 3$ (P = 0.89); $l^2 = 0\%$ Test for overall effect $Z = 0.68$ (P = 0.50) 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: $Chi^2 = 1.49$, $df = 2$ (P = 0.48); $l^2 = 0\%$ Test for overall effect $Z = 0.09$ (P = 0.93) 1.46 E Cordina provide consideration (provided information)	
Test for overall effect: $Z = 1.47$ (P = 0.14) 1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.67] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.68 (P = 0.89); I ² = 0% Test for overall effect: $Z = 0.68$ (P = 0.89); I ² = 0% Test for overall effect: $Z = 0.68$ (P = 0.50) 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); I ² = 0% Test for overall effect: $Z = 0.09$ (P = 0.93) 1.46 C cardia provide considence (wherd here is branced in Liferentian)	
1.16.3 Urinary tract infections Emery RJH 1991 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% CI) 198 219 27.2% 0.76 [0.34, 1.70] 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); P = 0% Test for overall effect: $Z = 0.68$ (P = 0.50) 1 15 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.76] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] 1.05 Total events 6 6 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% <t< td=""><td></td></t<>	
Emery Rule 0 27 1 26 3.0% 0.31 [0.01, 7.94] Khorami M 2016 1 22 1 29 1.6% 1.33 [0.08, 22.57] Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); P = 0% 7.2% 0.76 [0.29, 10.76] Test for overall effect Z = 0.68 (P = 0.50) 8 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% Ng ZD 2014 3 96 2 111 3.6% Ng ZD 2014 3 96 2 111 3.6% 1.076 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] Total events	-
Image: Normal constraint with 2010 1 22 1 23 1.05% 1.33 (U.08, 2.257) Ng ZD 2014 2 96 4 111 7.3% 0.57 [0.10, 3.18] Santini S 2005 8 53 9 53 15.3% 0.87 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); P = 0% Test for overall effect: Z = 0.68 (P = 0.50) 1.16.4 Decubitus Emery RJH 1991 1 27 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% 2 2 1.05 [0.35, 3.18] Total events 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P	
Ingle 2011 1 100 9 11 1.0% 0.37 [0.31, 2.46] Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); ² = 0% Test for overall effect: Z = 0.68 (P = 0.50) 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] Total events 6 6 6 6 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] Total events 6 6 6 6 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] 1.05 [0.35, 3.18]	
Subtotal (95% Cl) 198 219 27.2% 0.76 [0.34, 1.70] Total events 11 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); P = 0% 7.2% 0.76 [0.34, 1.70] Test for overall effect: Z = 0.68 (P = 0.50) 11 15 11.6.4 Decubitus 127.2% 0.26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] 1.05 [0.35, 3.18] Total events 6 6 6 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); P = 0% Test for overall effect: Z = 0.09 (P = 0.93) 145 E Cardia provide social data (cuto data is interaction); 145 E Cardia provide social data (cuto data is interaction);	
Total events 11 15 Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); I ² = 0% Test for overall effect: Z = 0.68 (P = 0.50) 1.6.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.05 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); I ² = 0% Test for overall effect: Z = 0.09 (P = 0.93) 1.45 E. Cardia accord accord actor (production by consord and information)	
Heterogeneity: Chi ² = 0.62, df = 3 (P = 0.89); ² = 0% Test for overall effect: Z = 0.68 (P = 0.50) 1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); ² = 0% Test for overall effect: Z = 0.09 (P = 0.93) 1.16 Conditional control for the duminic branchism	
1.16.4 Decubitus Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% CI) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi² = 1.49, df = 2 (P = 0.48); l² = 0% Test for overall effect: Z = 0.09 (P = 0.93)	
Emery RJH 1991 1 27 0 26 1.0% 3.00 [0.12, 77.03] Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi² = 1.49, df = 2 (P = 0.48); I² = 0% Test for overall effect: Z = 0.09 (P = 0.93)	
Ng ZD 2014 3 96 2 111 3.6% 1.76 [0.29, 10.75] Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi² = 1.49, df = 2 (P = 0.48); I² = 0% Test for overall effect: Z = 0.09 (P = 0.93)	
Santini S 2005 2 53 4 53 7.7% 0.48 [0.08, 2.74] Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi ^P = 1.49, df = 2 (P = 0.48); I ^P = 0% Test for overall effect: Z = 0.09 (P = 0.93) 4 45 5 Condition provides considential information.	
Subtotal (95% Cl) 176 190 12.3% 1.05 [0.35, 3.18] Total events 6 6 Heterogeneity: Chi² = 1.49, df = 2 (P = 0.48); l² = 0% 7 Test for overall effect: Z = 0.09 (P = 0.93) 1 16 E Cardia page/dia (and the formation)	
Total events 6 6 Heterogeneity: Chi ² = 1.49, df = 2 (P = 0.48); I ² = 0% Test for overall effect: Z = 0.09 (P = 0.93)	
Heterogeneity: Chr = 1.49, dt = 2 (F = 0.48); F = 0% Test for overall effect: Z = 0.09 (P = 0.93)	
4.45.5 Cardia pagular agaidento (arbithmio/mugardia) informia-"	
1. to.5 Cardiovascular accidents (arrhythmia/myocardiai infarctión)	
Choi JY 2016 1 115 2 65 5.1% 0.28 [0.02, 3.11]	
Figred W 2009 1 112 1 108 2.0% 0.96 [0.06, 15.61]	
Knorarni m 2016 3 22 1 29 1.5% 4.42 (0.43, 45.76)	
Ng ZD 2014 3 96 2 111 3 6% 1 76 [0.29 10 75]	
Santini S 2005 4 53 2 53 3.7% 2.08 [0.36, 11.88]	
Subtotal (95% Cl) 512 498 16.8% 1.62 [0.69, 3.82]	
Total events 13 8	
Heterogeneity: $Chr = 3.20$, $dr = 5$ ($P = 0.67$); $F = 0\%$ Test for overall effect: $Z = 1.10$ ($P = 0.27$)	
1.16.6 Respiratory failure	
Choi JY 2016 2 115 1 65 2.5% 1.13 [0.10, 12.74]	
Ng ZD 2014 1 96 0 111 0.9% 3.50 [0.14, 86.99]	
Subtotal (95% CI) 211 1/6 3.4% 1.77 [0.26, 11.89]	
101ai evenis 3 1 Haterongenity: Chiž - 0.30 df - 1 (P - 0.59) iž - 0%	
Test for overall effect: $Z = 0.58$ (P = 0.56)	
1.16.7 Deep venous thrombosis	
Lo WH 1994 3 96 4 111 7.2% 0.86 [0.19, 3.96]	
Ng ZD 2014 0 114 1 132 2.8% 0.38 [0.02, 9.49]	
Subtotal (95% Cl) 210 243 10.0% 0.73 [0.19, 2.84]	
Total events 3 5	
Test for overall effect: $Z = 0.46$ (P = 0.65)	
Total (95% Cl) 1978 1929 100.0% 1.04 [0.70, 1.53]	
Total events 50 48	
Heterogeneity: Chi ² = 13.19, df = 25 (P = 0.97); i ² = 0%	
Test for overall effects 2 = 0.18 (P = 0.85) Favours [cemented] Favours [unceme	100
restrict suburbub dimerences. On $r = 0.01$, $u_1 = 0$ ($P = 0.42$), $r = 0.236$	100 ented]

problem, especially for highly susceptible elderly patients. When we only included deep wound infections in our meta-analysis, there was no significant difference between CBH and UCBH corroborating the findings of Wu XJ et al. (40). Likewise, there was no significant difference in superficial wound infections between CBH and UCBH

(40). The meta-analysis of Sebastian S et al. (42) showed that antibiotic (gentamicin)-containing bone cement effectively reduced the incidence of prosthetic joint infections following hip arthroplasty. However, in our meta-analysis, the included studies did not indicate whether the bone cement contained antibiotics. Wound infection

Study of Subdroup	Events	nea Total	Unceme Events	ented Total	Weight	M-H, Fixed, 95% CL	Odds Ratio M-H. Fixed, 95% Cl
1.17.1 Perioperative r	nortality (within 72	Phours)	Total	Troight	in-ri, rixed, son er	
Fiaved W 2009	3	108	1	105	0.0%	2.97 (0.30, 29.03)	
Kristensen TB 2020	1	162	1	172	0.0%	1.06 [0.07, 17.12]	
Ng ZD 2014	272	22639	38	7539	1.6%	2.40 [1.71, 3.37]	
Talsnes O 2012	2	96	1	111	0.0%	2.34 [0.21, 26.22]	
Subtotal (95% CI)		23005		7927	1.6%	2.39 [1.71, 3.32]	•
Total events	278		41				
Heterogeneity: Chi ² = (Test for overall effect:)	0.36, df = 3 Z = 5.15 (F	3 (P = 0.9 P < 0.000	95); I² = 0 101)	1%			
1.17.2 1-week mortali	ity						
Figved W 2009	3	108	4	105	0.1%	0.72 [0.16, 3.30]	
Kristensen TB 2020	843	22639	233	7539	9.3%	1.21 [1.05, 1.41]	-
Movrin I 2020	7	79	3	79	0.1%	2.46 [0.61, 9.89]	
Subtotal (95% CI)		22826		7723	9.5%	1.22 [1.05, 1.41]	◆
Total events	853		240				
Heterogeneity: Chi ² = 1 Test for overall effect: 3	1.44, df = : 7 = 2.64 (F	2 (P = 0.4 P = 0.008	49); I² = 0 0	1%			
	2-2.04 ()	- 0.000	<i>,</i>				
1.17.3 1-month morta	lity		-				
Figved VV 2009	4	108	8	105	0.2%	0.47 [0.14, 1.60]	
Kristensen TB 2020	1985	22639	617	7539	23.4%	1.08 [0.98, 1.18]	T C C C C C C C C C C C C C C C C C C C
Subtotal (95% CI)		22/4/		7644	23.7%	1.07 [0.98, 1.18]	T I I I I I I I I I I I I I I I I I I I
Heterogeneity: Chi ² = 1 Test for overall effect: 2	1989 1.77, df = 1 Z = 1.46 (F	1 (P = 0.1 P = 0.14)	625 8); ² = 4	3%			
1.17.4 3-month morta	litv						
Emeny R.IH 1991		27	3	26	0.1%	1 33 (0 27 6 63)	
Figved W 2009	13	108	15	105	0.1%	0.82 [0.37 1.82]	
Subtotal (95% CI)	15	135	15	131	0.4%	0.90 [0.44, 1.84]	-
Total events	17		18				
Heterogeneity: Chi ² = (Test for overall effect: 2	0.28, df = Z = 0.28 (F	1 (P = 0.8 P = 0.78)	60); I² = 0	1%			
1.17.5 1-year mortality	y						
Figved W 2009	20	108	30	105	0.7%	0.57 [0.30, 1.08]	
Kristensen TB 2020	5572	22639	1898	7539	59.6%	0.97 [0.91, 1.03]	•
Lo WH 1994	21	189	11	258	0.0%	2.81 [1.32, 5.97]	
Ng ZD 2014	11	96	13	111	0.3%	0.98 [0.42, 2.29]	
Santini S 2005	13	53	14	53	0.3%	0.91 [0.38, 2.17]	
Song JSA 2019	42	361	36	296	1.0%	0.95 [0.59, 1.53]	
Talsnes O 2012	39	162	52	172	1.1%	0.73 [0.45, 1.19]	
Viberg B 2013	7	209	26	360	0.5%	0.45 [0.19, 1.04]	
Subtotal (95% CI)		23628		8636	63.4%	0.96 [0.90, 1.01]	•
Total events	5704		2069				
Heterogeneity: Chi ² = 7 Test for overall effect: 7	7.01, df = 1 Z = 1.47 (F	6 (P = 0.3 P = 0.14)	32); I ^z = 1	4%			
1 17 6 2 year mortalit	v						
Figved W 2000	, 20	109	26	105	07%	0.81 00 45 1 441	
Movrin L2020	32 27	70	20	70	0.730	0.01 [0.40, 1.44]	
Rai SK 2017	24 A	13	21	73 17	0.0%	2 11 [0 36 12 17]	
Subtotal (95% CI)	+	229	2	226	1.3%	0.87 [0.57. 1.33]	-
Total events	60	220	65	220		and former unal	
Heterogeneity: Chi ² = 1 Test for overall effect: J	1.05, df = : Z = 0.64 (F	2 (P = 0.5 P = 0.52)	59); I² = C	1%			
Total (95% CI)		92570		32287	100.0%	1.03 [0.99, 1.08]	•
Total events	8901		3058				
	48.94, df=	= 20 (P =	0.0003);	I ^z = 59%	, ,		
Heterogeneity: Chi ² = - Test for overall effect: 2 Test for subgroup diffe	Z = 1.32 (P erences: C	² = 0.19))hi² = 37	26. df = '	5 (P < 0)	10001) ⊫≊	= 86.6%	Favours [cemented] Favours [uncemented]

group.

after a hip arthroplasty was not only related to the operation time and the use of bone cement supplemented with antibiotics but also risk factors such as prolonged wound drainage, glucocorticoids, poor glycemic control, urinary/respiratory infections, chronic liver disease, and alcohol consumption (43). Clinically, the plan of hip replacement should include relevant prevention and control measures-detailed preoperative physical examinations to exclude possible hidden infectious lesions, strict intra-operative aseptic

operation, and standardized postoperative nursing-to not only reduce incidences of postoperative wound infection but also improve the treatment effect.

Bone cement implantation syndrome (BCIS) is a set of clinical symptoms caused by bone cement implantation that include hypoxia, sudden drop of arterial pressure, pulmonary hypertension, arrhythmias, loss of consciousness, and cardiac arrest (16). The pathophysiology of BCIS is not clear, but bone cement toxicity,





pulmonary embolisms, and lipid mediators are theorized to constitute its etiology. Moreover, physiological reactions and original pathological changes in patients are involved in its pathogenesis (16). BCIS is a potentially fatal complication of cemented hemiarthroplasty and confers a 16-fold increased chance of death within the 30-day postoperative period (16). Analysis of 25,000 hemiarthroplasties from the Australian registry (44) found that the early postoperative

mortality of patients was significantly higher for those who had underwent cemented than uncemented hemiarthroplasties, and the difference decreased with time. And they also found that patients older than 80 years of age had an increased risk of death after undergoing a cemented hemiarthroplasty. An analysis of 11,210, 19,669, and 25,174 hemiarthroplasties from the Norwegian (45), UK (46), and Finland registries (47) respectively found a higher first-day post-operation mortality for patients who had underwent cemented than uncemented hemiarthroplasties. Thus, for elderly patients, the use of the traditional bone cement hemiarthroplasty increases early postoperative mortality. In our meta-analysis, the perioperative mortality (within 72 h after operation) and 30-day postoperative mortality were significantly higher for CBH than UCBH. However, there were no significant differences in postoperative mortality between the two groups at 1 month, 3 months, 1 year, and 2 years. Wu XJ et al. (40) showed an association with higher mortality at 1 day, 1 week, and 1 month after operation for cemented than uncemented hemiarthroplasty. Langslet E et al. (26) found no significant difference in mortality at 5 years between the cemented and uncemented groups, but more high-quality studies are needed to corroborate this finding. Relatedly, Olsen F et al. (16) reported high American Society of Anesthesiologists (ASA) grade, chronic obstructive pulmonary disease, and medication with diuretics and warfarin as the independent preoperative risk factors for the development of BCIS and severe BCIS was associated with high early and late mortalities. Therefore, we should think about how to reduce the occurrence of BCIS in clinical work so as to reduce the mortality of patients. The application of bone cement is only just one of many factors that predispose the patient to postoperative mortalities. Most patients with FNFs are at an advanced age and in a generally poor condition often ailing from cardiovascular and cerebrovascular diseases, hypertension, diabetes, and lung diseases and low physical reserves, those are risk factors for higher mortality, demonstrating the importance of perioperative management of patients (48).

Cardiovascular and cerebrovascular accident complications and pulmonary embolisms were the main concerns for patients undergoing cemented hemiarthroplasty. Insertion of the prosthesis stem into the medullary cavity using the cemented technique, raised the intramedullary pressure, which accentuated fat embolization (49). Fat embolization caused hemodynamic imbalance and embolism of important organs, resulting in cerebral and myocardial infarctions, pulmonary embolisms, acute heart and respiratory failure, shock, and even sudden death both during operation and postoperatively (50). Mori K et al. (51) reported the sudden death of a patient due to severe fat embolization in the lung 4 h after the operation. Movrin I (25) showed that patients undergoing cemented than uncemented hemiarthroplasty were more likely to have a sudden drop in systolic blood pressure (\geq 30 mmHg) and in intraoperative SaO2 during the prosthesis stem insertion (18.9 vs. 5.1%, P = 0.007; 10.1 vs. 0.0%, P = 0.009). Relatedly, on study reported a patient experienced severe hypotension during the cementing procedure and died within 24 h of myocardial infarction (28). Therefore, some scholars believe that the elderly patients with significant cardiovascular risk factors should be given priority to the use of cementless bipolar hemiarthroplasty (52). A previous meta-analysis showed that the cemented hemiarthroplasty did not increase the risk of mortality, cardiovascular and cerebrovascular complications while achieving good postoperative results (53). Our meta-analysis obtained similar results that there were no significant differences in the incidence of pulmonary embolisms, cardiovascular accidents (arrhythmia/myocardial infarction), and respiratory failure between CBH and UCBH. In summary, there were several points that deserved mention when using bone cement, attention should be paid to the maintenance of the patient's blood volume at a normal level during anesthesia; stable blood pressure before using bone cement, and heightened monitoring during injection; before reaming or use of bone cement, flushing of the intramedullary contents with a pulsing

squirt gun and ensuring hemostasis *via* gauze compression to reduce the pressure in the medullary cavity; the appropriate speed of bone cement injection. In addition, our meta-analysis showed there were no significant differences between CBH and UCBH in incidences of other general complications such as pulmonary infections, urinary tract infections, deep venous thromboses, and decubitus. Both CBH and UCBH promoted get-out-of-bed activities early and reduced the incidence of bed-related complications.

The revision rates of prostheses is the most convincing current index for evaluation of the failure of hip arthroplasty. Deep infection, loosening of prosthesis, and femoral fracture lead to the failure of hip arthroplasty that in turn leads to revision surgery. Analysis of 11,116 patient records from the Norwegian Hip Fracture Registry found higher revision rates in the ucemented group than in the cemented group (54). Our meta-analysis found no significant difference in revision rates between CBH and UCBH. However, CBH was associated with lower incidences of intra-operative fractures, periprosthetic fractures after an operation, aseptic loosening of the prosthesis, and deep infections. Re-operation included revision that were mainly for periprosthetic fracture, aseptic loosening of the prosthesis, deep infection, dislocation of prosthesis, and wear of acetabular. However, re-operation also included the reduction of a dislocated prosthesis, debridement of superficial wound infection, and drainage of hematoma. Our meta-analysis found an association of lower re-operation rates for CBH than UCBH, corroborating the findings of Wu XJ et al. (40) and Gjertsen JE et al. (54). In our research, this lower re-operation rates may relate to lower incidences of wound infections. The stability of uncemented prosthesis depends on the contact scope and close degree between prosthesis and medullary cavity. Otherwise, resulting in either loosening or subsidence of the prosthesis results in the near future or in the long term. Elderly patients often ail from severe osteoporosis, and to stabilize the prosthesis, the surgeons constantly knock the prosthesis stem to tamp the prosthesis. This may lead to fracturing of the upper femur intra-operatively. Although the initial stability of uncemented prosthesis depends on well-matched bone tissue and prosthesis, it is difficult for elderly patients with severe osteoporosis to achieve this goal. This leads to increased chances of a loose prosthesis that poorly disperses the surrounding stress leading to periprosthetic fracture during weight-bearing walking (41). Therefore, accurate preoperative template measurement, careful surgical steps without the usage of major force, careful assessment of bone quality, and selection of appropriate prosthesis are extremely important for the treatment of FNFs in the elderly using hemiarthroplasty. Our metaanalysis showed no significant differences between CBH and UCBH in other prosthesis-related complications including dislocation of prosthesis, subsidence of prosthesis (> 5 mm), and acetabulum erosion. Kizkapan TB et al. (55) showed that bone cement usage does not affect the risk of dislocation after bipolar hemiarthroplasty, which was mainly related to the surgical approach and pelvic morphologic features. Age, placement position of the prosthesis, neurological disorders, abductor muscle weakness, hip joint deformities, the diameter of the artificial femoral head, and inappropriate posture are the other risk factors for the dislocation of prostheses (41, 55). Acetabular wear is a problem for hemiarthroplasty and thus total hip arthroplasty is the first option for patients younger than 70 years of age, although there is no clear age limit for use of either hemiarthroplasty or total hip arthroplasty. Moreover, it also needs to be comprehensively considered in combination with the patient's physical condition and daily activity. Thigh pain often occurs early

on after an uncemented hip arthroplasty (56), which may be related to the fretting of prosthesis in the early stage and the proportion of the prosthesis in the medullary cavity after implantation (57). Conversely, cemented fixation is associated with a low incidence of thigh pain due to the immediate stability of the prosthesis in the early stage. Our meta-analysis showed no significant difference between CBH and UCBH in the incidence of residual pain. This was because the assessment of thigh pain in the included studies happened at the last follow-up-by this time, the bone tissue had grown well into the uncemented prosthesis and achieved ultimate stability. This was corroborated by Campbell et al. (57) who showed that thigh pain was relieved with time when the uncemented prosthesis achieved a further fit with the medullary cavity. This indicated a reduced incidence of thigh pain when the uncemented prosthesis matched the medullary cavity well. Therefore, the selection of a fitting prosthesis greatly influences the prevention of thigh pain. Currently, a hydroxyapatite-coated femoral prosthesis has characteristics that better promote bone induction and bone ingrowth (58). Some studies (57, 59) showed that the interface between hydroxyapatite and the bone was combined firmly 3 weeks after hip arthroplasty, resulting in a sufficient and uniform fixation of the prosthesis in the medullary cavity. Heterotopic ossification is a common complication of hip arthroplasty. Although most of the patients have no obvious clinical symptoms, severe heterotopic ossification causes postoperative pain and decreased joint mobility (60). The pathogenesis of heterotopic ossification is unclear: injuries to the muscles, nerves, and other soft tissues during operation possibly transform fibroblasts to osteoblasts, resulting in heterotopic ossification (61). Our meta-analysis showed an association with a lower incidence of heterotopic ossification for UCBH than CBH, possibly because both the heat released by the polymerization of the bone cement and its cytotoxicity may stimulate the formation of heterotrophic ossification in the surrounding tissues (40). Non-steroid anti-inflammatory drugs can prevent the formation of heterotopic ossification (62). Therefore, the incidence of heterotopic ossification can be reduced by light and soft manipulations during operation to avoid excessive soft tissue damage, thorough flushing of the wound surface before closing the incision, and the preventive use of non-steroidal anti-inflammatory drugs after the operation.

5. Limitation

Our study had some limitations. First, there only six RCTs were included, and the rest were observational studies, which creating an inevitable bias. Second, it was difficult to strictly control for the blinding to the limitations of surgery. Therefore, better research plans, larger sample sizes, more multi-center RCTs, and longer follow-up durations are recommended for future meta-analyses. Third, all the included studies were published in English, resulting in possible language biases. Fourth, the size of the medullary cavity, the thickness of the bone cortex, and the severity of osteoporosis are important factors that affect the selection of prostheses for the treatment of FNFs in elderly patients. However, our meta-analysis did not analyze these factors, but only compared outcomes between CBH and UCBH. Finally, the general status, prosthesis type and surgical approach used on the patients differed, and coalesced results should thus be treated with caution.

6. Conclusion

In conclusion, patients with FNFs who were older than 60 years of age and underwent CBH were associated with longer operation time, more intra-operative blood loss, higher incidence of heterotrophic ossification and higher mortality within 72 h and 1-week after operation, but had lower incidences of periprosthetic fractures, aseptic loosening of prostheses, intra-operative fractures, postoperative wound infections, and re-operations than those who underwent UCBH. Conversely, the two groups did not significantly differ in terms of length of hospital stay, residual pain, dislocation of prosthesis, subsidence of prosthesis (> 5 mm), acetabulum erosion, revision rates, incidences of pulmonary infections, pulmonary embolisms, urinary tract infections, deep venous thromboses, decubitus, cardiovascular accidents (arrhythmia/myocardial infarction), respiratory failure, mortality at 1 month, 3 months, 1 year, and 2 years postoperatively. However, due to the limited numbers and types of included studies, the above conclusions need to be corroborated by numerous RCTs with large sample sizes and long-term follow-ups.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

MF and JW designed the project and prepared the manuscript. JS, MF, ZR, and YL were involved in data collection and data analysis. MF and WJ edited the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2023.1085485/ full#supplementary-material

10.3389/fmed.2023.1085485

References

1. Cheng S, Levy A, Lefaivre K, Guy P, Kuramoto L, Sobolev B. Geographic trends in incidence of hip fractures: a comprehensive literature review. *Osteoporos Int.* (2011) 22:2575–86. doi: 10.1007/s00198-011-1596-z

2. Veldman H, Heyligers I, Grimm B, Boymans T. Cemented versus cementless hemiarthroplasty for a displaced fracture of the femoral neck: a systematic review and meta-analysis of current generation hip stems. *Bone Joint J.* (2017) 99:421–31. doi: 10. 1302/0301-620X.99B4.BJJ-2016-0758.R1

3. Fenelon C, Murphy E, Pomeroy E, Murphy R, Curtin W, Murphy C. Perioperative mortality after cemented or uncemented hemiarthroplasty for displaced femoral neck fractures: a systematic review and meta-analysis. *J Arthroplasty.* (2021) 36:777–87. doi: 10.1016/j.arth.2020.08.042

4. Bhandari M, Devereaux P, Tornetta P III, Swiontkowski M, Berry D, Haidukewych G, et al. Operative management of displaced femoral neck fractures in elderly patients: an international survey. *J Bone Joint Surg Am.* (2005) 87:2122–30. doi: 10.2106/JBJS.E.00535

5. Inngul C, Blomfeldt R, Ponzer S, Enocson A. Cemented versus uncemented arthroplasty in patients with a displaced fracture of the femoral neck. *Bone Joint J.* (2015) 97:1475–80. doi: 10.1302/0301-620X.97B11.36248

6. Blomfeldt R, Törnkvist H, Eriksson K, Söderqvist A, Ponzer S, Tidermark J. A randomised controlled trial comparing bipolar hemiarthroplasty with total hip replacement for displaced intracapsular fractures of the femoral neck in elderly patients. *J Bone Joint Surg Br.* (2007) 89:160–5. doi: 10.1302/0301-620X.89B2.18576

7. Zhou Z, Yan F, Sha W, Wang L, Zhang X. Unipolar versus bipolar hemiarthroplasty for displaced femoral neck fractures in elderly patients. *Orthopedics.* (2015) 38:697–702. doi: 10.3928/01477447-20151016-08

8. Yang B, Lin X, Yin X, Wen X. Bipolar versus unipolar hemiarthroplasty for displaced femoral neck fractures in the elder patient: a systematic review and meta-analysis of randomized trials. *Eur J Orthop Surg Traumatol.* (2015) 25:425–33. doi: 10.1007/s00590-014-1565-2

9. Yoo J, Cha Y, Kim K, Kim H, Choy W, Hwang S. Comparison between cementless and cemented bipolar hemiarthroplasty for treatment of unstable intertrochanteric fractures: systematic review and meta-analysis. *Hip Pelvis.* (2018) 30:241–53. doi: 10.5371/hp.2018. 30.4.241

10. Elmenshawy A, Salem K. Cemented versus cementless bipolar hemiarthroplasty for femoral neck fractures in the elderly. *EFORT Open Rev.* (2021) 6:380–6. doi: 10.1302/2058-5241.6.200057

11. Ng Man Sun S, Gillott E, Bhamra J, Briggs T. Implant use for primary hip and knee arthroplasty: are we getting it right first time? *J Arthroplasty.* (2013) 28:908–12. doi: 10.1016/j.arth.2012.11.012

12. Frenken M, Schotanus M, van Haaren E, Hendrickx R. Cemented versus uncemented hemiarthroplasty of the hip in patients with a femoral neck fracture: a comparison of two modern stem design implants. *Eur J Orthop Surg Traumatol.* (2018) 28:1305–12. doi: 10.1007/s00590-018-2202-2

13. Li N, Zhong L, Wang C, Xu M, Li W. Cemented versus uncemented hemiarthroplasty for femoral neck fractures in elderly patients: a systematic review and meta-analysis of randomized controlled trials. *Medicine*. (2020) 99:e19039. doi: 10.1097/ MD.000000000019039

14. Kumar P, Rajnish R, Neradi D, Kumar V, Agarwal S, Aggarwal S. Hemiarthroplasty for neck of femur fractures: to cement or not? A systematic review of literature and metaanalysis. *Eur J Orthop Surg Traumatol.* (2019) 29:731–46. doi: 10.1007/s00590-019-02364-z

15. Clark D, Ahmed A, Baxendale B, Moran C. Cardiac output during hemiarthroplasty of the hip. A prospective, controlled trial of cemented and uncemented prosthese. *J Bone Joint Surg Br.* (2001) 83:414–8. doi: 10.1302/0301-620x.83b3.11477

16. Olsen F, Kotyra M, Houltz E, Ricksten S. Bone cement implantation syndrome in cemented hemiarthroplasty for femoral neck fracture: incidence, risk factors, and effect on outcome. *Br J Anaesth.* (2014) 113:800–6. doi: 10.1093/bja/aeu226

17. Moerman S, Mathijssen N, Niesten D, Riedijk R, Rijnberg W, Koëter S, et al. More complications in uncemented compared to cemented hemiarthroplasty for displaced femoral neck fractures: a randomized controlled trial of 201 patients, with one year follow-up. *BMC Musculoskelet Disord.* (2017) 18:169. doi: 10.1186/s12891-017-1526-0

18. Slobogean G, Stockton D, Zeng B, Wang D, Ma B, Pollak A. Femoral neck shortening in adult patients under the age of 55 years is associated with worse functional outcomes: analysis of the prospective multi-center study of hip fracture outcomes in China (SHOC). *Injury.* (2017) 48:1837–42. doi: 10.1016/j.injury.2017.06.013

19. Chen Q, Huang C, Zhang Y. The effect of intravertebral anesthesia on bone cement implantation syndrome in aged patients: a single-center 5-year retrospective study. *Medicine*. (2016) 95:e4775. doi: 10.1097/MD.00000000004775

20. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* (2015) 4:1. doi: 10.1186/2046-4053-4-1

21. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell (2011).

22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z

23. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in metaanalyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

25. Movrin I. Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures: a randomized controlled trial with two years follow-up. *Acta Orthop Traumatol Turc.* (2020) 54:83–8. doi: 10.5152/j.aott.2020.01.432

26. Langslet E, Frihagen F, Opland V, Madsen J, Nordsletten L, Figved W. Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures: 5-year followup of a randomized trial. *Clin Orthop Relat Res.* (2014) 472:1291–9. doi: 10.1007/s11999-013-3308-9

27. Talsnes O, Hjelmstedt F, Pripp A, Reikerås O, Dahl O. No difference in mortality between cemented and uncemented hemiprosthesis for elderly patients with cervical hip fracture. A prospective randomized study on 334 patients over 75 years. *Arch Orthop Trauma Surg.* (2013) 133:805–9. doi: 10.1007/s00402-013-1726-5

28. Figved W, Opland V, Frihagen F, Jervidalo T, Madsen J, Nordsletten L. Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures. *Clin Orthop Relat Res.* (2009) 467:2426–35. doi: 10.1007/s11999-008-0672-y

29. Santini S, Rebeccato A, Bolgan I, Turi G. Hip fractures in elderly patients treated with bipolar hemiarthroplasty: comparison between cemented and cementless implants. *J* Orthop Traumatol. (2005) 6:80–7. doi: 10.1007/s10195-005-0086-5

30. Emery R, Broughton N, Desai K, Bulstrode C, Thomas T. Bipolar hemiarthroplasty for subcapital fracture of the femoral neck. A prospective randomised trial of cemented Thompson and uncemented Moore stems. *J Bone Joint Surg Br.* (1991) 73:322–4. doi: 10.1302/0301-620X.73B2.2005165

31. Kristensen T, Dybvik E, Kristoffersen M, Dale H, Engesæter L, Furnes O, et al. Cemented or uncemented hemiarthroplasty for femoral neck fracture? data from the norwegian hip fracture register. *Clin Orthop Relat Res.* (2020) 478:90–100. doi: 10.1097/ CORR.00000000000826

32. Song J, Dillman D, Wilson D, Dunbar M, Richardson G. Higher periprosthetic fracture rate associated with use of modern uncemented stems compared to cemented stems in femoral neck fractures. *Hip Int.* (2019) 29:177–83. doi: 10.1177/1120700018772291

33. Rai S, Vikas R, Sharma V, Wani S, Varma R. Cemented vs uncemented modular bipolar hemiarthroplasty treatment for femoral neck fracture in elderly patients. *J Arthrosc Jt Surg.* (2017) 4:127–30. doi: 10.1016/j.jajs.2017.10.007

34. Choi J, Sung Y, Kim J. Comparative Study of bipolar hemiarthroplasty for femur neck fractures treated with cemented versus cementless stem. *Hip Pelvis.* (2016) 28:208–16. doi: 10.5371/hp.2016.28.4.208

35. Khorami M, Arti H, Aghdam A. Cemented versus uncemented hemiarthroplasty in patients with displaced femoral neck fractures. *Pak J Med Sci.* (2016) 32:44–8. doi: 10.12669/pjms.321.8461

36. Cicek H, Seyfettinoglu F, Kilicarslan K, Ogur H, Öztürk L, Ýnkaya E. What should be the preferred choice of hemiarthroplasty technique in American Society of Anesthesiologists (ASA) class III patients with femoral neck fractures? Cemented or cementless. *Injury*. (2015) 46:1567–70. doi: 10.1016/j.injury.2015.05.019

37. Ng Z, Krishna L. Cemented versus cementless hemiarthroplasty for femoral neck fractures in the elderly. *J Orthop Surg.* (2014) 22:186–9. doi: 10.1177/230949901402200214

38. Viberg B, Overgaard S, Lauritsen J, Ovesen O. Lower reoperation rate for cemented hemiarthroplasty than for uncemented hemiarthroplasty and internal fixation following femoral neck fracture: 12- to 19-year follow-up of patients aged 75 years or more. *Acta Orthop.* (2013) 84:254–9. doi: 10.3109/17453674.2013.792033

39. Lo W, Chen W, Huang C, Chen T, Chiu F, Chen C. Bateman bipolar hemiarthroplasty for displaced intracapsular femoral neck fractures. Uncemented versus cemented. *Clin Orthop Relat Res.* (1994) 302:75–82.

40. Wu X, Wang Y, Sun W, Tan M. Cemented and uncemented hemiarthroplasty for femoral neck fracture in elderly patients: a systematic review and meta-analysis. *Aging Clin Exp Res.* (2021) 33:2087–111. doi: 10.1007/s40520-020-01731-9

41. Kong X. Meta-analysis of the effect of cemented and uncemented hemiarthroplasty on displaced femoral neck fracture in the elderly. *Exp Ther Med.* (2020) 20:2173–83. doi: 10.3892/etm.2020.8921

42. Sebastian S, Liu Y, Christensen R, Raina D, Tägil M, Lidgren L. Antibiotic containing bone cement in prevention of hip and knee prosthetic joint infections:a systematic review and meta-analysis. *J Orthop Translat.* (2020) 23:53–60. doi: 10.1016/j.jot.2020.04.005

43. Ahmed S, Begum F, Kayani B, Haddad F. Risk factors, diagnosis and management of prosthetic joint infection after total hip arthroplasty. *Expert Rev Med Devices*. (2019) 16:1063–70. doi: 10.1080/17434440.2019.1696673

44. Costain D, Whitehouse S, Pratt N, Graves S, Ryan P, Crawford R. Perioperative mortality after hemiarthroplasty related to fixation method. *Acta Orthopaedica*. (2011) 82:275–81. doi: 10.3109/17453674.2011.584208

45. Talsnes O, Vinje T, Gjertsen J, Dahl O, Engesæter L, Baste V, et al. Perioperative mortality in hip fracture patients treated with cemented and uncemented hemiprosthesis: a register study of 11,210 patients. *Int Orthop.* (2013) 37:1135–40. doi: 10.1007/s00264-013-1851-3

46. Middleton R, Uzoigwe C, Young P, Smith R, Gosal H, Holt G. Peri-operative mortality after hemiarthroplasty for fracture of the hip does cement make a difference? *Bone Joint J.* (2014) 96:1185–91. doi: 10.1302/0301-620X.96B9.33935

47. Yli-Kyyny T, Sund R, Heinänen M, Venesmaa P, Kröger H. Cemented or uncemented hemiarthroplasty for the treatment of femoral neck fractures? *Acta Orthop.* (2014) 85:49–53. doi: 10.3109/17453674.2013.878827

48. Hossain M, Andrew J. Is there a difference in perioperative mortality between cemented and uncemented implants in hip fracture surgery? *Injury.* (2012) 43:2161–4. doi: 10.1016/j.injury.2012.08.043

49. Christie J, Burnett R, Potts H, Pell A. Echocardiography of transatrial embolism during cemented and uncemented hemiarthroplasty of the hip. *J Bone Joint Surg Br.* (1994) 76:409–12.

50. Rothberg D, Makarewich C. Fat embolism and fat embolism syndrome. *J Am Acad Orthop Surg.* (2019) 27:e346–55. doi: 10.5435/JAAOS-D-17-00571

51. Mori K, Sakaki J, Akizuki S, Horiuchi H. A case of pulmonary fat embolism and cardiac arrest after prosthetic replacement of the femoral stem. *Masui.* (1999) 48:416–8.

52. Marya S, Thukral R, Hasan R, Tripathi M. Cementless bipolar hemiarthroplasty in femoral neck fractures in elderly. *Indian J Orthop.* (2011) 45:236–42. doi: 10.4103/0019-5413.80042

53. Li T, Zhuang Q, Weng X, Zhou L, Bian Y. Cemented versus uncemented hemiarthroplasty for femoral neck fractures in elderly patients: a meta-analysis. *PLoS One.* (2013) 8:e68903. doi: 10.1371/journal.pone.0068903

54. Gjertsen J, Lie S, Vinje T, Engesæter L, Hallan G, Matre K, et al. More re-operations after uncemented than cemented hemiarthroplasty used in the treatment of displaced fractures of the femoral neck: an observational study of 11,116 hemiarthroplasties from

a national register. J Bone Joint Surg Br. (2012) 94:1113–9. doi: 10.1302/0301-620X.94B8. 29155

55. Kizkapan T, Misir A, Uzun E, Oguzkaya S, Ozcamdalli M. Factors affecting dislocation after bipolar hemiarthroplasty in patients with femoral neck fracture. *Injury.* (2020) 51:663–9. doi: 10.1016/j.injury.2020.01.025

56. Grosso M, Danoff J, Padgett D, Iorio R, Macaulay W. The cemented unipolar prosthesis for the management of displaced femoral neck fractures in the dependent osteopenic elderly. *J Arthroplasty*. (2015) 31:1040–6. doi: 10.1016/j.arth.2015.11.029

57. Campbell A, Rorabeck C, Bourne R, Chess D, Nott L. Thigh pain after cementless hip arthroplasty. Annoyance or ill omen. J Bone Joint Surg Br. (1992) 74:63–6. doi: 10.1302/0301-620X.74B1.1732268

58. Grammatopoulos G, Wilson H, Kendrick B, Pulford E, Lippett J, Deakin M, et al. Hemiarthroplasty using cemented or uncemented stems ofproven design: a comparative study. *Bone Joint J.* (2015) 97:94–9. doi: 10.1302/0301-620X.97B1.34138

59. Kim Y, Kim J, Oh S, Kim J. Comparison of porous-coated titanium femoral stems with and without hydroxyapatite coating. *J Bone Joint Surg Am.* (2003) 85:1682–8. doi: 10.2106/00004623-200309000-00005

60. Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. ANZ J Surg. (2003) 73:422–6. doi: 10.1046/j.1445-2197.2003.02647.x

61. Pavlou G, Salhab M, Murugesan L, Jallad S, Petsatodis G, West R, et al. Risk factors for heterotopic ossification in primary total hip arthroplasty. *Hip Int.* (2012) 22:50–5. doi: 10.5301/HIP.2012.9057

62. Pakos E, Ioannidis J. Radiotherapy vs. nonsteroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: a meta-analysis of randomized trials. *Int J Radiat Oncol Biol Phys.* (2004) 60:888–95. doi: 10.1016/j.ijrobp. 2003.11.015